Jukkola A, Bloigu R, Soini Y, Savolainen E R, Holli K, Blanco G
Department of Oncology, University of Oulu, Finland.
Eur J Cancer. 2001 Feb;37(3):347-54. doi: 10.1016/s0959-8049(00)00395-6.
The aim of this work was to evaluate the prognostic and predictive values of c-erbB-2 in breast cancer. 650 patients were enrolled. The amplification/overexpression of c-erbB-2 from fresh frozen or paraffin-embedded breast tumour tissue samples was analysed by polymerase chain reaction (PCR) technique (75%), immunohistochemically (17%) or by Southern blot analysis (8%). 126 patients (19%) were positive for c-erbB-2. 148 patients developed metastatic disease, but only 35 were positive for c-erbB-2. Positivity for c-erbB-2 was significantly associated with node positivity, large tumour size, high grade of malignancy, low receptor status, postmenopausal status, and with a shorter overall survival. In multivariate regression analysis, only tumour size and nodal involvement were risk factors for poor survival when analysed separately together with c-erbB-2 and receptor status. Metastatic patients with c-erbB-2 positivity had a significantly shorter survival and disease-free survival (DFS) than the c-erbB-2-negative patients. 29 advanced patients with c-erbB-2 positivity showed a poor response rate to hormonal, non-anthracycline-based and anthracycline-based therapies. Positivity for the c-erbB-2 is a poor prognostic factor in breast cancer, but it also emerges as predictive of the response to hormonal or chemotherapy treatment once the disease has recurred.
本研究旨在评估c-erbB-2在乳腺癌中的预后和预测价值。共纳入650例患者。采用聚合酶链反应（PCR）技术（75%）、免疫组织化学方法（17%）或Southern印迹分析（8%）对新鲜冷冻或石蜡包埋的乳腺肿瘤组织样本中的c-erbB-2扩增/过表达情况进行分析。126例患者（19%）c-erbB-2呈阳性。148例患者发生转移，但仅35例c-erbB-2呈阳性。c-erbB-2阳性与淋巴结阳性、肿瘤体积大、恶性程度高、受体状态低、绝经后状态以及总生存期较短显著相关。在多因素回归分析中，单独分析时，与c-erbB-2和受体状态一起，仅肿瘤大小和淋巴结受累是生存不良的危险因素。c-erbB-2阳性的转移患者的生存期和无病生存期（DFS）明显短于c-erbB-2阴性患者。29例c-erbB-2阳性的晚期患者对激素治疗、非蒽环类治疗和蒽环类治疗的反应率较低。c-erbB-2阳性是乳腺癌的不良预后因素，但在疾病复发后，它也可作为预测激素或化疗治疗反应的指标。
